First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimization analysis. [electronic resource]
Producer: 20150525Description: 362-8 p. digitalISSN:- 1477-092X
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Breast Neoplasms -- drug therapy
- Cost-Benefit Analysis
- Disease-Free Survival
- Docetaxel
- Drug Costs
- Female
- France
- Hospital Costs
- Hospitals, Private -- economics
- Hospitals, University -- economics
- Humans
- Kaplan-Meier Estimate
- Middle Aged
- National Health Programs -- economics
- Neoplasm Metastasis
- Paclitaxel -- administration & dosage
- Public Sector -- economics
- Retrospective Studies
- Taxoids -- administration & dosage
- Time Factors
- Transportation -- economics
- Trastuzumab
- Treatment Outcome
No physical items for this record
Publication Type: Comparative Study; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.